IDiyas

For the Inventor, By the Inventor

Berlin, Germany

Max-delbruck-centrum Fur Molekulare Medizin


USPTO Granted Patents = 30



Forward Citations = 71

Loading Chart...
Loading Chart...

91 inventors (with patents filed for the assignee):

goldMedal Regina Reszka (5 out of 10 patents)

silverMedal Zoltan Ivics (4 out of 9 patents)

bronzeMedal Michael Bader (4 out of 6 patents)

4.  Edgar Specker (3 out of 10 patents)

5.  Susann Matthes (3 out of 3 patents)

6.  Anja Schütz (3 out of 3 patents)

7.  Keven Mallow (3 out of 3 patents)

8.  Maik Grohmann (3 out of 3 patents)

9.  Marc Nazaré (3 out of 3 patents)

10.  Zsuzsanna Izsvak (3 out of 7 patents)

11.  Lajos Mates (3 out of 3 patents)

12.  Namitha Manoj (3 out of 3 patents)

13.  Carmen-Anisia Judis (3 out of 3 patents)

14.  Andrea Katzer (3 out of 3 patents)

15.  Robert Fischer (2 out of 7 patents)


30 patents:

1. 12370158 - Analogs of CYP-eicosanoids for use in treating or preventing a disorder associated with neovascularization and/or inflammation (2025-07-29),
2. 11661588 - Transposon, gene transfer system and method of using the same (2023-05-30),
3. 11096910 - Metabolically robust analogs of CYP-eicosanoids for the treatment of cardiac disease (2021-08-24),
4. 11028104 - Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same (2021-06-08),
5. 10745486 - Antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases (2020-08-18),
6. 10683309 - Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same (2020-06-16),
7. 10214530 - Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same (2019-02-26),
8. 9840696 - Nucleic acids encoding SB10 variants (2017-12-12),
9. 9708372 - Agonistic autoantibodies to the alpha1-adrenergic receptor and the beta2-adrenergic receptor in Alzheimer's and vascular dementia (2017-07-18),
10. 9512066 - Enhancers of protein degradation (2016-12-06),
11. 9228180 - Polypeptide variants of sleeping beauty transposase (2016-01-05),
12. 9085641 - Peptides regulating the surface expression of the T cell receptor (2015-07-21),
13. 8710088 - Pharmaceutical and diagnostic compositions for use in the treatment and diagnosis of neurodegenerative diseases or amyloid diseases (2014-04-29),
14. 8586054 - Method for modulating, treating and/or preventing metabolic syndrome using MAS-G-protein-coupled receptor agonists (2013-11-19),
15. 7951927 - Reconstructed human mariner transposon capable of stable gene transfer into chromosomes in vertebrates (2011-05-31),
The Max-Delbrück-Centrum für Molekulare Medizin (MDC) is a leading research center in the field of molecular medicine in Berlin, Germany. It focuses on biomedical research in order to understand the molecular underpinnings of health and disease. The MDC collaborates with universities, research institutions, and industry partners to translate its findings into therapeutic applications and medical innovations. Its research areas include cancer, cardiovascular diseases, neurodegenerative disorders, and more. Visit their website for more information and to explore their cutting-edge research advancements.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

30 Patents

#33 in D-1000 Berlin

#1,625 in Germany

#21,180 in the World

...
Berlin, Germany

Max-delbruck-centrum Fur Molekulare Medizin

Forward Citations = 71

91 inventors:

goldMedal Regina Reszka (5 out of 10 patents)

silverMedal Zoltan Ivics (4 out of 9 patents)

bronzeMedal Michael Bader (4 out of 6 patents)

4.  Edgar Specker (3 out of 10 patents)

5.  Susann Matthes (3 out of 3 patents)

Please report any incorrect information to support@idiyas.com
Loading…